Skip to main content

Table 2 Patient characteristics

From: Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL

Regimen

6xCIVEP-14

6xCHOEP-14

 

n=55

n=55

 

n (%)

n (%)

Male

28 (50.9%)

33 (60.0%)

Female

27 (49.1%)

22 (40.0%)

Age years median (range)

56 (23-71)

56 (25-73)

> 60 years

20 (36.4%)

20 (36.4%)

Histologies WHO classification

  

B-cell:

  

Diffuse large B-cell lymphoma

38

38

Follicular lymphoma III°/

7

6

Follicular lymphoma III° + DLBCL

  

NOS

3

7

Unclassified (insufficient mat.)

2

3

T-cell:

  

PTCL

1

1

No material/unclassified:

3/1

-

IPI

  

0,1

39(70.9%)

39 (70.9%)

2

11 (20.0%)

11 (20.0%)

3

2 (3.6%)

2 (3.6%)

4,5

3 (5.5%)

3 (5.5%)

Bulky disease

12 (21.8%)

13 (23.6%)

B-symptoms

14 (25.5%)

15 (27.3%)

Extranodal involvement

31 (56.4%)

31 (56.4%)

  1. In a matched pair analysis, pts recruited to CIVEP-14 and CHOEP-14 from the previously published NHL-B1/B2 trials were compared.